BRAF and melanoma: Moreover, NRAS-mutant melanoma, which constitutes ~25% of all melanoma cases, do not significantly benefit from those therapies, as they commonly lack oncogenic BRAF mutations and show a high degree of intrinsic resistance to MEKi [111,118].